Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 KT-621 Phase 2b trials in AD and asthma on track to initiate in 4Q25 and 1Q26, respectively WATERTOWN, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral sm ...

RBC Capital Markets launched its coverage of Kymera Therapeutics (NASDAQ:KYMR) with an Outperform rating on Tuesday, citing the potential of its lead drug KT-621, targeted at inflammatory conditions such as atopic dermatitis, commonly known as eczema. RBC analyst Brian Abrahams ...

Analyst Ratings Changes - Compass Point analyst Dominick Gabriele initiated coverage on Klarna Group plc (KLAR) with a Buy rating and a price target of $53, while Klarna shares closed at $45.48 [4] - DA Davidson analyst Wyatt Swanson initiated coverage on Clear Secure, Inc. (YOU) with a Buy rating and a price target of $45, with Clear Secure shares closing at $37.82 [4] - Wolfe Research analyst Tracy Benguigui initiated coverage on Chubb Limited (CB) with an Outperform rating and a price target of $320, as Chubb shares closed at $274.33 [4] - RBC Capital analyst Brian Abrahams initiated coverage on Kymera Therapeutics, Inc. (KYMR) with an Outperform rating and a price target of $70, while Kymera Therapeutics shares closed at $47.28 [4] - Wolfe Research analyst Tracy Benguigui also initiated coverage on The Travelers Companies, Inc. (TRV) with a Peer Perform rating, with Travelers shares closing at $276.30 [4]

Kymera Therapeutics Conference Call Summary Company Overview - **Company**: Kymera Therapeutics (NasdaqGM:KYMR) - **Focus**: Development of oral small molecule degraders for immunology, particularly targeting STAT6 and IRF5 programs [2][4][30] Key Points and Arguments STAT6 Program - **Current Status**: The company is advancing its STAT6 program, with a Phase 1B study ongoing and a Phase 2B study planned for atopic dermatitis [2][3][10] - **Phase 1 Healthy Volunteer Study**: Completed with positive results, achieving over 90% degradation of STAT6, which is crucial for blocking the IL-4/13 pathway [11][16] - **Comparison to DUPIXENT**: The STAT6 degrader (KT-621) aims to replicate the efficacy of DUPIXENT, which has shown success in treating TH2 allergic diseases [10][11] - **Biomarker Analysis**: The study also focused on TH2 biomarkers like TARC and eotaxins to validate the degradation impact [12][14] Financial Position - **Capitalization**: Kymera exited July 2025 with approximately $1 billion on its balance sheet, providing a runway into the second half of 2028 [4][5] - **Funding Programs**: The capital supports ongoing and future programs, including the STAT6 and IRF5 studies [5][39] Mechanism of Action - **Degraders vs. Small Molecule Inhibitors**: Degraders utilize the ubiquitin proteasome system, allowing for more effective and selective protein degradation compared to traditional small molecule inhibitors [6][8][9] Phase 1B Study Objectives - **Goals**: To confirm the translation of STAT6 degradation from healthy volunteers to atopic dermatitis patients and to assess the impact on TH2 biomarkers [18][21] - **Dose Selection**: The study includes multiple doses to ensure robust data for Phase 2B dose selection [19][23] Regulatory and Market Considerations - **Placebo Effect**: The company is aware of the placebo responses in atopic dermatitis studies and is implementing stringent eligibility criteria to mitigate this risk [24][25] - **Future Studies**: Plans for Phase 2B studies include dose range finding and pivotal registrational studies [33][40] IRF5 Program - **Target Indications**: IRF5 is positioned for different diseases, including lupus and rheumatoid arthritis, with promising preclinical data [30][31] - **Pipeline Strategy**: The company aims to develop a portfolio of oral immunology drugs, enhancing potential combination therapies [31] Collaboration and Milestones - **Partnership with Sanofi**: Sanofi is advancing a second-generation degrader (KT-485) while Kymera continues to develop its own pipeline [37][41] - **Milestones**: Future milestones from partnerships are not included in the current financial runway but could provide additional funding [41] Additional Important Insights - **Execution Focus**: The company emphasizes the importance of executing a strong Phase 2B study to elucidate the activity of KT-621 [28] - **Timeline Expectations**: Data from the Phase 2B study is unlikely to be available before 2026 due to typical enrollment and follow-up durations [29] This summary encapsulates the key discussions and insights from the Kymera Therapeutics conference call, highlighting the company's strategic focus, financial health, and ongoing clinical developments.

PresentationAll right. Good afternoon, everyone. Welcome to this session of the Morgan Stanley Global Healthcare Conference. I'm Judah Frommer, one of the SMID biotech analysts here. Let me just get through a quick disclosure before welcoming Kymera. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. With that, welcome, Nello and Jared. And ...

Summary of Kymera Therapeutics FY Conference Call Company Overview - **Company**: Kymera Therapeutics (NasdaqGM:KYMR) - **Industry**: Biotechnology, specifically focused on targeted protein degradation technology Key Points and Arguments 1. **Technology Platform**: Kymera utilizes a protein degrader platform to develop new medicines targeting previously undrugged or poorly drugged proteins, focusing on small molecule modalities that allow for cellular penetration [3][4] 2. **Target Focus**: The company targets pathways with high validation and significant patient impact, particularly in oncology and immunology, aiming to create oral drugs with biologic-like activity [4][5] 3. **Pipeline Development**: Kymera's pipeline includes KT-621, a first-in-class oral STAT6 degrader, which has the potential to impact over 100 million patients [5][6] 4. **Initial Data from KT-621**: Phase 1 study showed over 90% degradation of the target with a favorable safety profile, outperforming expectations and demonstrating significant effects on TH2 biomarkers [8][9] 5. **Unmet Need**: Despite Dupilumab's presence in the market, over 90% of patients with conditions like asthma and atopic dermatitis lack access to effective treatments due to the high cost and inconvenience of injectable biologics [9][10] 6. **Phase 1B Study Goals**: The ongoing Phase 1B study aims to confirm degradation in patients, translate findings from healthy volunteers, and demonstrate clinical endpoints comparable to existing biologics [15][18] 7. **Cash Position**: As of July, Kymera has approximately $1 billion in cash, sufficient to fund operations into the second half of 2028, supporting various studies and pipeline activities [43] Additional Important Content 1. **IRF5 Program**: Kymera is advancing its IRF5 program, targeting diseases like lupus and rheumatoid arthritis, with plans to enter Phase 1 trials in early next year [38][39] 2. **Collaboration with Gilead**: The company has a CDK2 collaboration with Gilead, which is not a strategic focus for Kymera but represents a valuable asset [44] 3. **Regulatory Environment**: Concerns were raised about the lack of a level playing field between small molecules and biologics, emphasizing the need for clarity and fairness in the regulatory landscape [52][53] 4. **AI Utilization**: Kymera is leveraging AI to enhance efficiency in its operations, focusing on practical applications rather than just theoretical capabilities [51] Conclusion Kymera Therapeutics is positioned to address significant unmet medical needs through its innovative protein degradation technology, with a strong pipeline and financial backing to support its development efforts. The company is committed to advancing its programs independently while remaining aware of the competitive landscape and regulatory challenges.

Kymera Therapeutics (KYMR) FY 2025 Conference September 04, 2025 09:30 AM ET Company ParticipantsNello Mainolfi - Founder, President, CEO & DirectorJared Gollob - Chief Medical OfficerConference Call ParticipantsDerek Archila - MD, Co-Head - Therapeutics Research & Senior Biotechnology AnalystDerek ArchilaAll right, everyone. I think we'll get started with the next fireside here. My name is Derek Archila. I'm one of the senior biotech analysts here at Wells. Very excited to have Chimera Therapeutics with us ...

Financial Data and Key Metrics Changes - The company is focused on delivering a new generation of medicines, particularly in immunology, with a significant unmet need in the market for advanced systemic therapies [4][5] - The company has shown that its STAT6 program can match the efficacy of existing biologics like dupilumab, with a focus on oral degraders that can block pathways effectively [6][10] Business Line Data and Key Metrics Changes - The company has shifted its focus to immunology over the past five years, with all recent and preclinical programs targeting this area [4] - The STAT6 program is the most advanced in the pipeline, with two Phase 2b studies planned to start soon [6][10] Market Data and Key Metrics Changes - There are over 100 million patients in the seven major markets suffering from immune inflammatory diseases, with only about 3% having access to advanced therapies [5] - The company aims to address this gap with its oral degraders, which are expected to provide a paradigm shift in treatment options [5] Company Strategy and Development Direction - The company is committed to protecting its franchise by ensuring flawless execution and continuing to develop its drug pipeline [43][44] - The company has a second-generation molecule that is IND ready, which could expand its franchise in the future [44] Management's Comments on Operating Environment and Future Outlook - Management believes that the company has the potential to develop a best-in-class Th2 drug, with clear expectations for the upcoming Phase Ib study [12][13] - The competitive landscape is evolving, but the company feels confident in its unique position and the effectiveness of its STAT6 program [42][46] Other Important Information - The company is exploring opportunities in other therapeutic areas, including Th1 diseases and autoimmune conditions, where there is a lack of effective oral drugs [52] - The management emphasizes the importance of understanding the unique features of their drug and its mechanism in the context of ongoing research [31][32] Q&A Session Summary Question: What are the expectations for the Phase Ib study? - The management expects to demonstrate that STAT6 degradation leads to significant impacts on Th2 cytokines comparable to existing biologics like dupilumab [12][13] Question: How does the company plan to differentiate itself in the competitive landscape? - The company believes it has a strong position due to its advanced programs and the effectiveness of its STAT6 drug, which is difficult for competitors to surpass [42][46] Question: What are the eligibility criteria for the Phase Ib study? - The study will include patients with moderate to severe atopic dermatitis, with specific criteria aligned with previous studies to ensure a relevant patient population [32][33] Question: How does the company view the potential for its second-generation molecule? - The second-generation molecule is seen as both an insurance policy and a potential tool for expanding the franchise, although the focus remains on the current STAT6 program [44][45] Question: What is the company's approach to targeted protein degradation? - The company is focused on matching technology with unmet medical needs and is exploring various avenues for targeted protein degradation, including molecular glues and tissue-selective E3 ligases [56][58]

PresentationGeoffrey MeachamManaging Director Here we go. So welcome to the second day of the Citi Biopharma, the Back to School Conference. I'm Geoff Meacham. My team is here with me as well. I'm the senior biopharma analyst. So our next session is Kymera Therapeutics. We're thrilled to have CEO, Nello Mainolfi, President and CEO, sorry; and then Jared Gollob, CMO; Justine from the IR team. Bruce may or may not be here. So maybe, Nello, thanks for joining us, by the way. ...

Kymera Therapeutics (KYMR) Conference September 03, 2025 10:30 AM ET Company ParticipantsGeoff Meacham - Managing DirectorNello Mainolfi - Founder, President, CEO & DirectorJared Gollob - Chief Medical OfficerConference Call ParticipantsNone - AnalystGeoff MeachamSo welcome to the second day of the Citi Biopharma, the back to school conference. I'm Jeff Micho. My my team's here, with me as well. I'm the senior biopharma analyst.So our next session, is Chimera Therapeutics. We're thrilled to have, CEO, Nelo ...